The European Food Safety Authority this morning said it has concluded that meat and milk from healthy cloned cattle and pigs is "very unlikely" to pose risks to consumers, opening the door to possible European sales of those controversial foods in the future.
The highly anticipated draft scientific opinion of the European agency comes just days before the U.S. Food and Drug Administration is due to release its final report on the same topic, which is expected to come to virtually the same conclusion. Some backers of the fledgling agricultural cloning industry have said they hoped that a positive report from Europe might ease the process of gaining acceptance by American consumers.
It remains unclear, however, whether the European Union will ultimately approve the sale of cloned products, and if so under what conditions.
Unlike the case in the United States, such decisions in Europe are required by law to incorporate social and ethical considerations. And the European public broadly supports the so-called precautionary principle, which calls for society to err on the side of caution when risks are uncertain.
Moreover, the European agency, which provides scientific advice to the European Commission, notes in its report that many cloned farm animals have health problems, including life-threatening physiological abnormalities. In Europe, where animal welfare is a much higher profile issue than it is in the United States, that reality could also become a stumbling block.
Read the full Washington Post story here.
Latest from Quality Assurance & Food Safety
- USDA Indefinitely Delays Salmonella Testing Program for Raw Breaded Stuffed Chicken
- American Soybean Association Names New Industry Relations Leadership
- Babybel Transitions From Cellophane to Paper Packaging
- Ambriola Company Recalls Cheese Products Due to Listeria Risk
- Horizon Family Brands Acquires Maple Hill Creamery
- Kellanova Shares Top Five Consumer Packaged Goods Tech Trends Shaping 2026
- Stay Ahead of Supply Chain Pressure
- Brendan Niemira Named IFT Chief Science and Technology Officer